Cargando…
Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice
BACKGROUND: The objective of this study was to develop a ligand-targeted photodynamic therapy (tPDT) by conjugating factor VII (fVII) protein with photosensitiser verteporfin in order to overcome the poor selectivity and enhance the effect of non-targeted PDT (ntPDT) for cancer. fVII is a natural li...
Autores principales: | Hu, Zhiwei, Rao, Benqiang, Chen, Shimin, Duanmu, Jinzhong |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882923/ https://www.ncbi.nlm.nih.gov/pubmed/20504328 http://dx.doi.org/10.1186/1471-2407-10-235 |
Ejemplares similares
-
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy
por: Hu, Zhiwei, et al.
Publicado: (2016) -
Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy
por: Duanmu, J, et al.
Publicado: (2011) -
Photodynamic Therapy with Verteporfin for Corneal Neovascularization
por: Al-Torbak, Abdullah A.
Publicado: (2012) -
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
por: Jain, Prashant, et al.
Publicado: (2018) -
Commentary: Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
por: Kumar, Atul, et al.
Publicado: (2018)